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Objectives: To determine the frequency of tuberculosis and malignancy in transudative pleural effusions. 
Material and Method: The study was conducted in Pulmonology-OPD, Gulab Devi Teaching Hospital Lahore 
from Oct. 2017 to Feb. 2019.  One hundred and twenty-eight consecutive patients with transudative pleural 
effusions and 14-69 years age, willing for invasive investigations & ADA estimation were included, while those 
not willing for further investigations, participation in the study, and exudative effusions were excluded. The 
clinical features, pleural fluid analysis findings, ADA (Adenosine deaminase) estimation results, hematology, 
echocardiography, bronchoscopy, Lymph node biopsy, CT-thorax, ultrasound chest & abdomen results were 
recorded on a preformed proforma. Findings were summarized, tabulated, and analyzed statistically using SPSS-
16 software. 
Results:  Out of 1370 cases of pleural effusion, 128 cases (9.34%) with pleural transudate were isolated.  In all 
patients, pleural fluid protein/serum protein level was < 0.5.  The age ranged 14-69 years with a mean of 39 years 
+ 11.3. Fifty-two cases (40.62%) had right-sided, 38 cases (29.68%) left-sided while 38 cases (29.68%) had bilateral 
pleural effusions. Seventy-six aspirates (59.37%) were yellow, 20 (15.62%) reddish, 18 (14.06%) straw-colored and 
14 fluids (10.93%) were watery in color. Out of 128 transudative effusions, malignant etiology was found in 23 
cases (17.96%), tubercular in 17 cases (13.28%) and 19 cases (14.84%) of Para-pneumonic origin were detected. 
Conclusion: Tuberculosis and malignancy can be the possible etiology of transudative effusion. 
Keywords:  Pleural transudate, Malignancy, Systemic disorders, TB. 




A pleural effusion is always due to underlying disease 
and can be exudative or transudative, depending upon 
the pleural fluid protein and serum protein content. 
Classification into exudate or transudate is usually 
done according to the Light’s criteria. Transudative 
pleural effusions develop when the hydrostatic and 
oncotic pressures across the pleural membrane are 
disturbed & dynamic equilibrium between the fluid 
formation and absorption is lost.  There is no change in 
the pleural membrane, the endothelium is usually 
intact and cells & protein content of effusion is low.1-4 
About 5-25% of total pleural effusions are usually 
transudative in nature.5 According to conventional 
teaching, this effusion is considered mainly due to 
cardiac, hepatic, renal, and systemic disorders.6-7 But 
tuberculosis and malignancy can also be infrequent 
etiology.8 Malignant cells have been detected in a 
significant number of transudates, representing 
advanced malignant processes with high morbidity 
and mortality, precluding the possibility of treatment 
with a curative approach. Metastatic adenocarcinoma 
is the commonest histological finding, while the 
primary tumor is not identified in approximately 10% 
of patients of malignant pleural effusions.9-10  
Similarly, cases with tubercular etiology have also 
been reported in transudates and pleural fluid 
estimation of ADA (Adenosine deaminase) level is 
found a good diagnostic tool for TB diagnosis.11-12 
Because of this association of malignancy and TB 
(Tuberculosis) with transudative PE, pleural fluid 
cytology and Adenosine deaminase (ADA) estimation 
should be employed for all transudative pleural 
effusions.11,13  We designed this study to identify and 
compute the proportion of TB and malignancy 
associated with transudative pleural effusions.  
 
Materials and Methods 
 
Objectives: To determine the frequency of tubercular 
and malignant etiology in transudative pleural 
effusions & also to evaluate the need for performing 
cytology and ADA estimation in pleural transudates. 
Study Design:  Prospective study. 
Patients and Methods: This study was conducted at 
the out-patient department of Respiratory Medicine, 
Gulab Devi Chest Hospital Lahore a 1500 bedded 
tertiary care hospital, from October 2017 to February 
2019.   
Inclusion criteria: A total of 128 consecutive adult 
patients, with 14-69 years of age, no obvious evidence 
of TB or malignancy, no history of diuretic therapy, 
with transudative pleural effusion, willing for invasive 
investigations, and participation in the study, were 
included. 
Exclusion criteria:  Patients below 14 years, exudates, 
incomplete data, on diuretic therapy, not willing for 
ADA estimation, invasive investigation or 
participation in the study and known cases, or having 
radiological suspicion of tubercular or malignant 
etiology were excluded. 
Method: The study was approved ethically by the IRB 
of the hospital vide No. Admin/GDEC/18.491 and 
conducted over a period of 17-months. Detailed 
clinical history including cigarette smoking and 
contact with a TB-patient were recorded. A thorough 
physical examination was performed. Chest x-ray-PA 
and Lateral views, ultrasound abdomen, pelvis, and 
chest were done which was followed by ultrasound-
guided pleural aspiration, and the fluid sample was 
sent for biochemistry including ADA & LDH 
estimation, cytology, and bacteriology. CBC with ESR, 
Serum Protein, serum LDH, LFTs, RFTs, thyroid 
function tests, and viral markers for hepatitis was 
performed in pertinent cases. Sputum was evaluated 
by Gram stain, Z-N stain & cytology. Light’s Criteria 
was applied for differentiating transudate from 
exudate. 
A transudative pleural effusion was defined by 
meeting at least one of the following criteria: 1. Pleural 
fluid protein/serum protein level < 0.5., 2. Pleural 
fluid LDH level < 2/3 of the upper limits of the normal 
serum value. 3. Pleural fluid LDH/serum LDH value 
< 0.6. 
ECG, Echocardiography, CT-thorax, Bronchoscopy & 
biopsy along with BAL (Broncho-alveolar lavage) 
cytology were employed for precise diagnosis, in 
pertinent cases. Lymph node biopsy and 
histopathology were carried out in the required cases. 
Pleural fluid culture & sensitivity was utilized to 
isolate pyogenic etiology. Pleural fluid ADA level, 40 
IU/L and above was considered as the cut-off for TB-
diagnosis. Tubercular patients were put on anti-TB 
therapy via standard DOTS regimen and were 
followed for six months. The response to treatment 
was noted. Fluid immuno-staining and cytopathology 
diagnosed malignant etiology.   
All clinical findings were recorded in the pre-formed 
proforma. Data was summarized; organized, 
tabulated, and SPSS-16 software was used for 
statistical analysis to reach the conclusion. Descriptive 
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Out of 1370 cases of pleural effusion, 128 cases (9.34%) 
with pleural transudate were isolated.  In all patients, 
pleural fluid protein/serum protein level was < 0.5.  
The age ranged 14-69 years with a mean of 39 years + 
11.3. Eighty-six patients (67.18%) were male while 42 
patients (32.81%) were female. The male to female 
ratio was 2:1. Majority of the patients presented with 
respiratory complaints (Table 1). Cigarette smoking 
(73.43%), history of contact with a TB-patient (10.15%), 
and Diabetes Mellitus (30.46%) were major risk factors. 
 
Table 1: Clinical presentation in 128 patients 




1. Chest pain. 115 89.84 
2. Cough  102 79.68 
3. Fever 97 75.78 
4. Shortness of 
breath  
93 72.65 
5. Weight loss 70 54.68 
6. Loss of Appetite 62 48.43 
 
Fifty-two cases (40.62%) had right-sided, 38 cases 
(29.68%) left-sided while 38 cases (29.68%) had 
bilateral pleural effusions. Seventy-six aspirates 
(59.37%) were yellow, 20 (15.62%) reddish, 18 (14.06%) 
straw-colored and 14 fluids (10.93%) were watery in 
color. Cytology and bacteriology of 128 pleural fluids 
are tabulated (Table 2). BAL analysis revealed 
malignant cells in 03 cases while 01 case was 
diagnosed as TB on Gene-Xpert. Out of 04, two lymph 
node biopsies showed lymphoma and two caseation 
granuloma. 
 
Table 2: Pleural Fluid Cytology and Bacteriology 
n=128 






1. Lymphocytic 102 79.68 % 
2. Neutrophillic 26 20.31 % 
3. Malignant 
cytology 
18 14.06 % 
Pleural Fluid Bacteriology in 19 patients  
1. Streptococcus 
Pneumonie 
06 31.57 % 
2. Staphylococcus 
Aureus 
05 26.31 % 
3. Gram –ve  Rods 03 15.78 % 
4. Pseudomonas 03 15.78 % 
5. No-growth 02 10.52 % 
*n= total pyogenic transudates. 
 
Out of 128 transudates, 105 patients (82.03%) were 
diagnosed with non-malignant while 23 cases (17.96 




Table 3: Frequency of non-malignant pathologies with ADA values n=105 
No Diagnosis Observed 
Cases  
Percentage of 
(n)*         
ADA Range 
IU/L 
Mean ADA value 
IU/L 
1. TB  PE 17 16.19 % 34-85.6 55.86 
2. Para-pneumonic 19 18.09 % 07-11 09.2 
3. Cardiogenic cause 35 33.33 % 07-16 8.66 
4. CLD 13 12.38 % 07-18 12.95 
5. CRF 10 9.52 % 9.8-12 11.34 
6. Hypo-proteinemia 03 2.85 % 14-19 16.5 
7.  Non Specific 04 3.80 % 12-15.5 13.7 
8. SLE 03 2.85 % 17-18 17.4 
9. Rheumatoid  Arthritis 01  0.95 % 14.0 14.0 
* Percentage is calculated for 105 non-malignant transudates. 
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While investigating an undiagnosed pleural effusion, 
biochemistry is utilized for deciding exudative or 
transudative nature & transudate fluids are 
investigated by keeping a focus on systemic causes 
without including tuberculosis and malignancy in the 
list of differential diagnosis because of their 
documented exudative nature.14-15 
This study last for a 17-month period during which 
1370 pleural effusions were investigated and 128 cases 
(9.34%) of pleural transudates were isolated, which 
included 35 cases (27.34%) cardiac, 23 cases (17.96%) 
malignant, and 19 cases (14.84%) of Para-pneumonic 
origin while 17 cases (13.28%) with tubercular etiology 
were also obtained.   
The study population had a mean age of 39 years + 
11.3 and two of third patients were men. This age 
along with (73.43%) cigarette smoking and (30.46%) 
diabetes mellitus favor cardiac and renal etiology. We 
had 35/128 cases with cardiogenic and 10/128 cases 
with renal etiologies in our study. As smoking is more 
common in men, we had 67.18% of patients with the 
male gender. Smoking is started early in childhood in 
males than in females, they consume more pack-year 
and are more vulnerable to the risk of smoking as 
compared to females. We had 73.43% of patients with 
smoking, which is itself an established risk factor for 
cardiac and malignant disorders.16-17 
Ferreiro L et al reported the prevalence of malignant 
transudative pleural effusion as 10% (18), Ashchi M et 
al reported as 4.6% among 171 malignant pleural 
transudates.19 Yuri Moltyaner et al displayed 8% 
malignancy20 while our series exhibited a prevalence 
of 17.96% malignancy, in 128 transudates.  
The possible explanation for malignant transudate 
formation is that initially fluid is accumulated due to 
lymphatic-obstruction; low protein level-ultra-filtrate 
is formed without pleural seeding with malignant foci. 
Confounding co-morbidities like heart failure may also 
be responsible for transudate formation. Similarly, any 
tumor or lymph node causing bronchial obstruction 
and atelectasis can result in transudate formation.21 
Commonly the tumor of lung, breast, and lymphoma 
invading mediastinal lymph nodes cause lymphatic 
obstruction, resulting in transudate formation.22-23 
Bayhan Gl and colleagues concluded their study by 
commenting that pleural TB can present in the form of 
transudates.24 Doerr CH and co-workers reported 27% 
of patients with benign tumors, tuberculosis, and heart 
failure, for transudative effusions.25 Agrawal V 
reported 14.28% tubercular transudates.26 A Spanish 
study of 3077 cases during 19 years, revealed 9.0% 
etiology due to tuberculosis.27 We found 13.28% 
tubercular etiology in 128 transudates (19 months 
period) which is fairly comparable with these studies. 
In this study, 13/17 cases (76.47%) diagnosed as 
tuberculosis had a history of contact with a TB patient 
in their family, which created a high index of suspicion 
about tubercular etiology. Tuberculosis was diagnosed 
by pleural fluid ADA level in all cases except three 
with border-line values, two were diagnosed by lymph 
node biopsy and one case was detected by BAL Gene-
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Xpert. As tuberculosis is endemic in our region, all 
exudative lymphocytic pleural effusions are 
considered as tubercular, until proven otherwise.28 But 
transudative effusions are dealt with differently. On 
finding a transudative pleural effusion, the diagnostic 
plan is oriented toward systemic causes while TB & 
malignancy are over-looked, that is why transudates 
with TB and malignant pathologies remain 
undetected.  It is very much pertinent to make this 
note that tuberculosis is a curable disease if diagnosed 
timely, if it is missed, it can be a risk for the patient 
and the community as well. As pleural fluid ADA 
estimation is a useful biomarker for TB diagnosis in 
endemic areas, it should be frankly utilized for the 
workup of all TB-suspect transudates.29  
Similarly, malignant pleural effusions are almost 
always categorized as exudates. The presence of 
malignant cells in transudative effusion indicates a 
mitotic lesion with high-grade morbidity & mortality 
with a brief expected life span (only 4–9 months), that 
is why a timely diagnosis of such patients is valuable 
for the patient as well as for the treating physician. It 
can only be achieved by having a high index of 
suspicion. \Although, British Thoracic Society does 
not recommend thoracentesis for bilateral pleural 
effusions, suspected to be transudate, if sampled, BTS 
suggests cytology for all.30 Porcel J.M. and associates 
analyzed 840 malignant effusions and found that 
cytology was 59% accurate in detecting malignancy.31-
32 In our study, 18/23 cases (78.26%) of malignancy 
were diagnosed by pleural fluid cytology, 03 cases 
(13.04%) by BAL cytology, and 02/23 cases were 
diagnosed by lymph node biopsy. Moltyaner Y et al. 
suggested that every transudate should be 
investigated by cytology to maximize the diagnostic 
yield.20 The traditional teaching suggests performing 
cytology on a transudative pleural effusion in search 
of a malignant cause, might not be cost-effective. In the 
current era of cost-effective medicine, it is mandatory 
to ensure that we should not sacrifice the quality of 
care for cost. Therefore, pleural fluid cytology seems to 
be essential in all transudative effusions to avoid the 
chances of missing malignant pathologies. 
Additionally, ADA estimation can be very much 
helpful in differentiating between malignant and 
tubercular transudates.  
19/128 cases (14.84%) of transudate with pyogenic 
etiology is an eye-opening figure. Bacteriologic work-
up (Table-II) reflecting the internal story, thus 
necessitates the need for culture and sensitivity 
examination for all pleural transudate.  It is, therefore, 
suggested that in the absence of any obvious systemic 
etiology, all transudative pleural effusions must be 
subjected to fluid cytology, bacteriology & ADA 
estimation.  
The main limitation of this study is that it is a single-
center study performed on limited sample size 
(n=128). By further elongation of the study or a study 
with larger sample size and preferably, a multi-center 
study can further explore the subject and strengthen 
the study. 
Our results can find very useful applications in 
populations with a high prevalence of tuberculosis and 
increasing malignant disorders due to heavy smoking, 
industrialization, environmental and occupational 
pollution, for diagnostic as well as disease control 
objectives.   
In the light of this discussion, we have no hesitation in 
commenting that a transudative pleural effusion is just 
a false re-assurance against malignancy and 
tuberculosis. Therefore, all pleural transudates must 
be investigated from the perspective of tuberculosis 





• Tuberculosis and malignancy can be the 
possible etiology of transudative pleural effusions. 
• Pleural fluid cytology and ADA estimation & 
pyogenic culture and sensitivity should be included in 
the diagnostic algorithm of transudative pleural 
effusions. 
• The history of contact with a TB patient must 
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